(Q46448567)

22 December 2017

title

Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis (English)

1 reference

22 December 2017

0 references

1 reference

Dimitrios P Kontoyiannis

1

object named as

Dimitrios P Kontoyiannis

1 reference

22 December 2017

author name string

Maha Boktour

2

1 reference

22 December 2017

Hend Hanna

3

1 reference

22 December 2017

Harrys A Torres

4

1 reference

22 December 2017

Ray Hachem

5

1 reference

22 December 2017

Issam I Raad

6

1 reference

22 December 2017

language of work or name

English

0 references

publication date

1 June 2005

1 reference

22 December 2017

number of pages

4

1 reference

inferred from page(s)

published in

Cancer

1 reference

22 December 2017

volume

103

1 reference

22 December 2017

issue

11

1 reference

22 December 2017

page(s)

2334-2337

1 reference

22 December 2017

Effects of antifungal agent combinations administered simultaneously and sequentially against Aspergillus fumigatus

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21057

The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21057

Use of amphotericin B with azole antifungal drugs: what are we doing?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21057

Invasive aspergillosis in 2002: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21057

7 January 2021

Aspergillosis case-fatality rate: systematic review of the literature

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21057

7 January 2021

Combination chemotherapy for invasive fungal infections: what laboratory and clinical studies tell us so far.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21057

7 January 2021

Itraconazole-amphotericin B antagonism in Aspergillus fumigatus: an E-test-based strategy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21057

7 January 2021

Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21057

7 January 2021

Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21057

7 January 2021

Amphotericin B refractory aspergillosis after itraconazole: evidence for significant antagonism

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21057

7 January 2021

Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21057

7 January 2021

New agents for treatment of invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21057

7 January 2021

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21057

7 January 2021

Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21057

7 January 2021

Amphotericin B with and without itraconazole for invasive aspergillosis: A three-year retrospective study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21057

7 January 2021

Identifiers

DOI

10.1002/CNCR.21057

1 reference

22 December 2017

1 reference

22 December 2017